Table 1.
Recent randomized, placebo-controlled studies concerning psilocybin and esketamine in depression.
| Author, Year | Substance | Phase | No. Part. | Condition |
|---|---|---|---|---|
| Griffiths, R. 2016 [41] | Psilocybin | Phase 2 | 51 | Depression and/or anxiety |
| Ross, S. 2016 [42] | Psilocybin | Early Phase 1 | 29 | Depression and/or anxiety |
| Carhart-Harris, R. 2021 [43] | Psilocybin | Phase 2 | 59 | Moderate-to-severe Major Depressive Disorder |
| Daly, E.J. 2018 [26] | Esketamine | Phase 2 | 57 | Treatment Resistant depression |
| Canuso, C.M. 2018 [33] | Esketamine | Phase 2 | 68 | Treatment Resistant Depression with Suicide Ideation |
| Fedgchin, M. 2019 [34] | Esketamine | Phase 3 | 346 | Treatment Resistant Depression |
| Popova, V. 2019 [35] | Esketamine | Phase 3 | 227 | Treatment Resistant depression |
| Daly, E.J. 2019 [36] | Esketamine | Phase 3 | 297 | Treatment Resistant depression |
| Fu, D-J. 2020 [37] | Esketamine | Phase 3 | 226 | Treatment Resistant Depression with Suicide Ideation |
| Ochs-Ross, R. 2020 [38] | Esketamine | Phase 3 | 51 | Treatment Resistant Depression |
| Takahashi, N. 2021 [39] | Esketamine | Phase 3b | 202 | Treatment Resistant Depression |
| Ionescu, D.F. 2021 [40] | Esketamine | Phase 3 | 230 | Treatment Resistant Depression with Suicide Ideation |